These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 181351)

  • 1. Characteristics of immunity induced by neuraminidase-treated lymphosarcoma cells in C3H (MTV+) and C3H (MTV-) mice.
    Bekesi JG; Roboz JP; Holland JF
    Isr J Med Sci; 1976; 12(4-5):288-303. PubMed ID: 181351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effectiveness of neuraminidase-treated tumor cells as an immunogen in man and experimental animals with leukemia.
    Bekesi JG; Roboz JP; Holland JF
    Ann N Y Acad Sci; 1976; 277(00):313-31. PubMed ID: 1069551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of in vitro and in vivo studies of antigens relevant to the control of murine breast cancer.
    Stutman O
    Cancer Res; 1976 Feb; 36(2 pt 2):739-47. PubMed ID: 175934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Increased immunologic reactivity against hepatoma 22A cells in MTV-infected C3H mice in comparison to MTV-free mice].
    Lavrovskiĭ VA; Viksler VKh
    Biull Eksp Biol Med; 1980 Oct; 90(10):467-9. PubMed ID: 6252986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced immune reactivity to hepatoma 22a cells in MTV-infected compared with MTV-free C3H mice.
    Lavrovsky VA; Viksler VK
    Immunology; 1981 Dec; 44(4):671-6. PubMed ID: 6274791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virus-dependent cytostatic activity to mammary tumor cells of lymphocytes from normal mice.
    Gillette RW; Lowery LT
    Cancer Res; 1976 Nov; 36(11 Pt 1):4008-14. PubMed ID: 184922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro detection of immune responses to MTV-induced mammary tumors: qualitative differences in response detected by time studies.
    Blair PB; Lane MA
    J Immunol; 1975 Jan; 114(1 Pt 1):17-23. PubMed ID: 163276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of cytotoxic effector cells in the mouse mammary tumor system.
    Lane MA; Roubinian J; Slomich M; Trefts P; Blair PB
    J Immunol; 1975 Jan; 114(1 Pt 1):24-9. PubMed ID: 46242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The specificity of concomitant tumor immunity at large tumor volumes.
    Deckers PJ; Pardridge DH; Wang BS; Mannick JA
    Cancer Res; 1976 Oct; 36(10):3690-4. PubMed ID: 953994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
    Fujiwara H; Fukuzawa M; Yoshioka T; Nakajima H; Hamaoka T
    J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
    Lynch DH; Daynes RA; Hodes RJ
    J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.
    Campbell MJ; Esserman L; Byars NE; Allison AC; Levy R
    J Immunol; 1990 Aug; 145(3):1029-36. PubMed ID: 2373859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural immunity in the oncornavirus-infected mouse.
    Blair PB
    Cancer Res; 1976 Feb; 36(2 pt 2):734-8. PubMed ID: 175933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of secondary cellular immunity to a tumor allograft by cyclophosphamide and 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Einstein AB; Fass L; Fefer A
    Cancer Res; 1975 Mar; 35(3):492-6. PubMed ID: 1078784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-T cell killing of mammary tumor cells by spleen cells: secretion of antibody and recruitment of cells.
    Blair PB; Lane MA
    J Immunol; 1975 Jul; 115(1):184-9. PubMed ID: 168254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normal tissue alloantigens and genetic control of susceptibility to tumors: microcytotoxicity studies on resistant C3Hf and susceptible (A X C3Hf) F1 mice inoculated with transplacentally induced C3Hf lung tumor.
    Martin WJ; Esber E; Cotton WG; Rice JM
    J Immunol; 1975 Jul; 115(1):289-295. PubMed ID: 50354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-mediated immunity in flavivirus infections. I. Induction of cytotoxic T lymphocytes in mice by an attenuated virus from the tick-borne encephalitis complex and its group-reactive character.
    Gajdosová E; Oravec C; Mayer V
    Acta Virol; 1981 Jan; 25(1):10-8. PubMed ID: 6165230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complexity of factors in sera of different mice that affect MTV-induced mammary tumor cells.
    Blair PB; Lane MA; Mar P
    J Immunol; 1976 Mar; 116(3):610-4. PubMed ID: 176267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of the Gardner lymphosarcoma for the mice of the strain C3H (H-2k). II. Alteration of the growth and dissemination of solid Gardner lymphosarcoma following immunization by an extract of the ascitic tumor.
    Motycka K; Bostík J; Bures L; Slavík K; Jirásek A
    Neoplasma; 1986; 33(2):177-85. PubMed ID: 3754937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mammary tumor virus oncogenesis and tumor immunogenicity in three sublines of the C3H mouse.
    Vaage J; Medina D
    Cancer Res; 1978 Aug; 38(8):2443-7. PubMed ID: 208767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.